Reformulation of OxyContin (Resolution No. 98-1-02)

May 23, 2002 3:05 PM Topics: Resolutions

Resolution No. 98-1-02
Title: Reformulation of OxyContin

Whereas, state boards of pharmacy are reporting an increase in the diversion of OxyContin and crimes related to that diversion, which place patients, the public, pharmacists, and staff members, at risk; and

Whereas, in prior instances, when abuse and diversion associated with a specific medication has occurred, strategies for decreasing abuse potential through appropriate pharmaceutical reformulation or withdrawal of that medication have been employed to address this problem;

Whereas, state boards of pharmacy recognize that OxyContin can be effectively used in the treatment of intractable pain and support patient access to this drug;

THEREFORE BE IT RESOLVED that NABP urge Purdue Pharma to clarify for the state boards of pharmacy their plans to address the abuse of OxyContin to make it less susceptible to abuse;

BE IT FURTHER RESOLVED that NABP encourage the Food and Drug Administration (FDA) to act expeditiously to consider any NDA or ANDA that will result in the reduction in the abuse potential of OxyContin.

(Resolution passed at NABP’s 98th Annual Meeting, Phoenix, AZ)